Cumulative triglyceride-glucose-body mass index exposure and cardiovascular disease risk: findings from the Kailuan study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Association of Cumulative Exposure to Triglyceride-Glucose-Body Mass Index and Cardiovascular Disease Risk: Insights from the Kailuan Study

  • By

  • Peng Fu

  • Yuxian Wang

  • Kuangyi Wu

  • Huancong Zheng

  • Zegui Huang

  • Weiqiang Wu

  • Zefeng Cai

  • Ning Wang

  • Hong Zheng

  • Haixiang Zheng

  • Bo Zhang

  • Shouling Wu

  • Youren Chen

  • July 13, 2026

Share

  • 1

    The study analyzed data from 47,577 individuals in the Kailuan Study to investigate cumulative TyG-BMI exposure and CVD risk.

  • 2

    Cumulative TyG-BMI exposure was calculated as the weighted sum of mean TyG-BMI across three health examinations.

  • 3

    A total of 3,514 cardiovascular events occurred during a median follow-up of 10 years, with increased risk linked to higher TyG-BMI quartiles.

  • 4

    Cox regression analysis showed hazard ratios for CVD risk of 1.32, 1.33, and 1.44 for higher TyG-BMI quartiles compared to the lowest.

  • 5

    The area under the ROC curve for cumulative TyG-BMI was 0.6047, indicating modestly better predictive performance than TyG and BMI alone.

Original Source(s)

Cumulative triglyceride-glucose-body mass index exposure and cardiovascular disease risk: findings from the Kailuan study

  • by Peng Fu, Yuxian Wang, Kuangyi Wu, Huancong Zheng, Zegui Huang, Weiqiang Wu, Zefeng Cai, Ning Wang, Hong Zheng, Haixiang Zheng, Bo Zhang, Shouling Wu, Youren Chen

  • July 13, 2026

Related Content

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Reliability and device objectivity in oscillatory blood pressure measurement – a measurement error analysis to inform clinical decision making

TOFA may drive weight loss without reducing food intake

The oral compound increased energy expenditure, reduced fat mass, and improved metabolic measures in male mouse models.